Island Pharmaceuticals (ASX:ILA) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Debt-to-Asset?

Island Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.00 Mil. Island Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$0.00 Mil. Island Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was A$4.31 Mil. Island Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Island Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Island Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Debt-to-Asset Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

0.17

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial				0.03	-	0.29	0.17	-

Competitive Comparison of Island Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Island Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Island Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Island Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Island Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.422	+	0)	/	2.564
	=	0.16

Island Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	4.31
	=	0.00

Island Pharmaceuticals (ASX:ILA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Island Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines